David Kim Portfolio
Invests via Paradigm Biocapital Advisors LP | Managed by Senai Asefaw, M.D., David Kim
Invests via Paradigm Biocapital Advisors LP
Managed by Senai Asefaw, M.D., David Kim
Automatically Tracked
David Kim Profile
With a strong foundation in technology and finance, David Kim has established himself as an influential figure in the startup ecosystem. His entrepreneurial journey began with the launch of multiple successful tech ventures, driving innovation in software solutions. As a seasoned operator, he emphasizes leveraging disruptive technologies to address market needs and create scalable business models. Kim's strategic leadership is evidenced by his ability to cultivate partnerships that accelerate growth and enhance competitive positioning within emerging sectors. Through mentorship roles and active investment participation, he remains committed to nurturing new talent and ideas that redefine industry standards.
With a strong foundation in technology and finance, David Kim has established himself as an influential figure in the startup ecosystem. His entrepreneurial journey began with the launch of multiple successful tech ventures, driving innovation in software solutions. As a seasoned operator, he emphasizes leveraging disruptive technologies to address market needs and create scalable business models. Kim's strategic leadership is evidenced by his ability to cultivate partnerships that accelerate growth and enhance competitive positioning within emerging sectors. Through mentorship roles and active investment participation, he remains committed to nurturing new talent and ideas that redefine industry standards.
Investment Philosophy & Strategy
David Kim's investment perspective thrives at the intersection of innovation and technology-driven growth. With a keen eye for identifying transformative startups, he actively seeks out companies poised to disrupt traditional markets. Emphasizing scalability, his approach combines rigorous analysis with an entrepreneurial mindset, focusing on building robust business models that respond dynamically to customer demands. His operational expertise allows him to assess potential partnerships and strategic alignments effectively, fostering environments ripe for rapid development. Kim champions ideas that challenge conventions and pave the way for future trends within the tech landscape.
David Kim's investment perspective thrives at the intersection of innovation and technology-driven growth. With a keen eye for identifying transformative startups, he actively seeks out companies poised to disrupt traditional markets. Emphasizing scalability, his approach combines rigorous analysis with an entrepreneurial mindset, focusing on building robust business models that respond dynamically to customer demands. His operational expertise allows him to assess potential partnerships and strategic alignments effectively, fostering environments ripe for rapid development. Kim champions ideas that challenge conventions and pave the way for future trends within the tech landscape.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
204.48%
Gain -1.24%
Monthly
2.36%
Yearly
32.33%
Drawdown
43.1%
$4.99B
Equity
Holdings
$4.99B
Investment
$2.95B
$2.55B
Profit -$35.44M
Realized
$499.64M
Unrealized
$2.05B
Dividends
$0
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-1.24%
Profit
-$35.44M
Win %
65%
This Week
Compared To Last Week
Gain
-0.69%
Profit
-$34.65M
Win %
65%
This Month
Compared to last month
Gain
-0.12%
Profit
-$5.87M
Win %
65%
This Year
Compared to last year
Gain
25.69%
Profit
$1.02B
Win %
66%
VRDN Viridian Therapeutics Inc.
+4.99%
+$2.83M 
BLTE Belite Bio, Inc.
+3.69%
+$6.16M 
URGN Urogen Pharma Ltd.
+2.97%
+$2.03M 
OLMA Olema Pharmaceuticals Inc.
+0.52%
+$481,234.56 
INSM Insmed Inc.
+0.22%
+$301,077.12 
MAZE Maze Therapeutics Inc.
+0.21%
+$164,663.94 
CYTK Cytokinetics, Incorporated
+0.21%
+$249,228.23 
APGE Apogee Therapeutics Inc.
+0.09%
+$155,047.95 
ERAS Erasca, Inc.
+0.05%
+$103,927.02 
ACLX Arcellx, Inc.
0%
$0 
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
0%
$0 
NUVL Nuvalent, Inc.
0%
$0 
TERN Terns Pharmaceuticals, Inc.
0%
$0 
VOR Vor Biopharma Inc.
-4.8%
-$1.52M 
GPCR Structure Therapeutics Inc.
-4.3%
-$1.14M 
KLRS Kalaris Therapeutics, Inc.
-4.11%
-$126,000 
ASMB Assembly Biosciences Inc.
-3.77%
-$671,903.51 
TARS Tarsus Pharmaceuticals Inc.
-3.76%
-$5.76M 
MANE Veradermics Inc.
-3.36%
-$1.96M 
EYPT EyePoint Pharmaceuticals Inc.
-3.29%
-$1.37M 
BBOT BridgeBio Oncology Therapeutics, Inc.
-3.27%
-$243,099.64 
LXEO Lexeo Therapeutics Inc.
-3.2%
-$927,620.1 
IVA Inventiva S.A.
-2.81%
-$520,000 
TNGX Tango Therapeutics Inc.
-2.68%
-$3.07M 
TYRA Tyra Biosciences, Inc.
-1.99%
-$1.32M 
GMAB Genmab A/S Sponsored ADR
-1.86%
-$4.26M 
MIRM Mirum Pharmaceuticals Inc.
-1.77%
-$1.31M 
EWTX Edgewise Therapeutics, Inc.
-1.37%
-$4.01M 
ABVX Abivax SA ADR
-1.35%
-$1.43M 
PCVX Vaxcyte, Inc.
-1.13%
-$3.05M 
SRRK Scholar Rock Holding Corporation
-0.95%
-$619,170.4 
RVMD Revolution Medicines Inc.
-0.89%
-$10.98M 
SYRE Spyre Therapeutics, Inc.
-0.8%
-$1.57M 
ORIC Oric Pharmaceuticals Inc.
-0.75%
-$136,097.36 
ORKA Oruka Therapeutics, Inc.
-0.66%
-$1.42M Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 486 | Longs Won 236/486 48% | Profit Factor 5.2 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $27.54M |
| Average Win $13.36M | Best Trade (Jul 19) $377.92M | Sharpe Ratio -17.64 |
| Average Loss -$2.43M | Worst Trade (Jul 19) -$69.25M | Z-Score -1.12 (73.7%) |
| Commissions $0 | Avg. Trade Length 11m 3w 5d | Expectancy $5.24M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.07% |
| Consecutive Losing Trades | 2,058 | 1,852 | 1,646 | 1,440 | 1,235 | 1,029 | 823 | 617 | 412 | 206 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for David Kim?
The largest contributions to the portfolio's profits come from the following stocks: argenx SE American Depositary Receipt - $97.86M, Alpine Immune Sciences Inc - $92.53M, Cogent Biosciences, Inc - $70.86M, Crinetics Pharmaceuticals Inc - $64M, and Autolus Therapeutics plc American Depositary Receipt - $57.99M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Janux Therapeutics Inc - $77.38M, Arvinas Inc - $61.12M, Vor Biopharma Inc - $37.73M, Immatics N.V - $28.92M, and Incyte Corporation - $21.12M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are David Kim's monthly returns?
David Kim's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can David Kim's strategy be considered aggressive or moderate?
David Kim's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow David Kim's strategy?
David Kim's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
